Compare AstraZeneca plc (AZN) vs Select Medical Holdings Corporation (SEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Select Medical Holdings Corporation — how do they compare? AstraZeneca plc trades at $166.5 (market cap $253.13B), while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: AstraZeneca plc is far larger — about 123.5× Select Medical Holdings Corporation's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | SEM | |
|---|---|---|
Market Cap | $253.13B | $2.05B |
Sector | Health | Health |
52-Week High | $209.48 | $16.66 |
52-Week Low | $137.44 | $11.77 |
Enterprise Value | $279.37B | $5.01B |
Dividend Yield | 1.92% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Select Medical Holdings (SEM) trades at $16.51, unchanged on the day, following its recent acquisition completion by a consortium led by Robert A. Ortenzio and Martin F. announced on June 30, 2026. The stock shows mixed signals with a bullish overall technical outlook but bearish moving averages, while fundamentals indicate modest profitability with a net income margin of 2.42% and a P/E ratio of 15.43. Recent earnings have been inconsistent, with Q1 2026 missing expectations.
The acquisition at $16.50 per share caps near-term upside, with legal investigations into board fiduciary duties posing reputational risks. Analyst sentiment is neutral with a 57.15% hold rating, reflecting uncertainty post-buyout. Investors face limited growth prospects amid stable revenues and margin pressures, emphasizing caution in the current holding pattern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →
